Grace Therapeutics, Inc. GRCE
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -46.53%
- 1 year
- -39.14%
- Market cap
- 38.92M
- EPS (ttm)
- -1.17
- Shares out
- 10.14M
- Forward P/E
- -2.90
- YTD return
- -46.53%
- 1-year return
- -39.14%
- Volume
- 114.88K
- Avg volume
- 130.37K
- Open
- 1.85
- Previous close
- 1.78
- Day's range
- 1.79 – 1.90
- 52-week range
- 1.78 – 5.13
- Beta
- 1.51
- Analysts
- Strong Buy
- Price target
- 10.44 (+464.6%)
- Earnings date
- Feb 10, 2025
5D -0.04 (-2.12%)
Key statistics
- Enterprise value
- 14.15M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.58M
- Total cash
- 19.41M
- Total debt
- 0
- Return on equity
- -18.56%
- Short % of float
- 1.60%
- 50-day average
- 3.44
- 200-day average
- 3.04
Analyst view
Consensus: strong buy
- Target (low)
- 7.79
- Target (mean)
- 10.44
- Target (high)
- 12.30
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 10, 2025
Expected Feb 10, 2025. Consensus EPS estimate -0.45333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2025 | Dec 1, 2024 | -0.27 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | -0.33 | -0.33 | 0.00 | 0.00% |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- acastipharma.com
News
Your note
Sign in to keep a note on GRCE — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Adar1 Capital Management, LLC | 9.46% | 959,571 | 3.51M | Sep 29, 2024 |
| AIGH Capital Management LLC | 6.32% | 641,083 | 2.35M | Sep 29, 2024 |
| Bank of America Corporation | 4.88% | 494,698 | 1.81M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.16% | 16,147 | 59.10K | Sep 29, 2024 |
| National Bank of Canada/FI | 0.03% | 2,719 | 9.95K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 2,732 | 10.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 3,058 | 11.19K | Oct 30, 2024 |